It was found to not provide sufficient protection against HIV to young women in sub-Saharan Africa, adding to the setbacks endured by those working in the field.
The Imbokodo study, which was at the mid-stage of development, included 2,600 women participants across five Southern African countries.
Women and girls accounted for more than 60% of all new HIV infections in the regions last year, making them a top priority when it came to the vaccine’s development.
Despite the disappointing result of this trial, J&J confirmed that it was continuing to research the safety and efficacy of another experimental HIV vaccine.